Biotech

Biotech Jonathan Wosen

STAT Plus: After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives

Biotech Elaine Chen

STAT Plus: Novo Nordisk’s amylin pill leads to substantial weight loss in early study

The Readout Meghana Keshavan

STAT Plus: Five biotech news stories you need to read today

Biotech Adam Feuerstein

STAT Plus: Viridian drug achieves study goals as treatment for thyroid eye disease

Biotech Adam Feuerstein

STAT Plus: Roivant acquires drug for pulmonary hypertension from Bayer

Biotech Timmy Broderick

STAT Plus: Q&A: Atsena Therapeutics’ gene therapy for inherited blindness shows promise

The Readout Meghana Keshavan

STAT Plus: Terns’ GLP-1 pill leads to weight loss in early study

Biotech Adam Feuerstein

STAT Plus: Merck executive plays down impact of new lung cancer drug data on Keytruda

Biotech Allison DeAngelis

STAT Plus: RayzeBio, Dice alums raise $370 million for new autoimmune startup

Biotech Angus Chen

STAT Plus: Relay discloses encouraging results for experimental breast cancer treatment

Biotech Matthew Herper

STAT Plus: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights

Biotech Jonathan Wosen and Adam Feuerstein

STAT Plus: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial

Biotech Adam Feuerstein

STAT Plus: Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients

Pharma Jason Mast

STAT Plus: U.K. charities give $36 million to start new drugs for childhood tumors 

Pharma Matthew Perrone and Nicky Forster — Associated Press

STAT Plus: Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after Covid delays

The Readout Meghana Keshavan

STAT Plus: Lilly has more positive data on its weekly insulin

Adam's Take Adam Feuerstein

STAT Plus: Alnylam versus BridgeBio: The ATTR-CM debate

Biotech Adam Feuerstein

STAT Plus: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal

Health Elaine Chen and Allison DeAngelis

STAT Plus: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target

Biotech Helen Branswell

STAT Plus: Moderna reports encouraging results on its mpox vaccine, as outbreaks in Africa spread

The Readout Elaine Chen

STAT Plus: BioMarin’s big day today

Exclusive Allison DeAngelis

STAT Plus: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance

Biotech Jason Mast

STAT Plus: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial

Biotech Matthew Herper

STAT Plus: Vaxcyte shares boom as one of biotech’s big David vs. Goliath stories heats up

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read this morning

Biotech Allison DeAngelis

STAT Plus: Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition

Biotech Andrew Joseph

STAT Plus: European court sides with Illumina, saying regulators overstepped in scrutiny of Grail deal

Special Report Matthew Herper

Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades

Biotech Matthew Herper

STAT Plus: Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions